NittoPhase™ HL
Since its introduction in 2004, the NittoPhase™ product line has established itself as a leading solid support for therapeutic oligonucleotide synthesis, with proven performance in commerical production at scales up to 400 mmol. Building on this foundation, NittoPhase™ HL extends the platform with a high-loading solid support that pushes the limits of solid-phase oligonucleotide synthesis.
The exceptional loading capacity of NittoPhase™ HL enables higher synthesis scales per column volume while maintaining the superior yields and full-length purity associated with the NittoPhase™ platform. This efficiency and meaningful reductions in overall synthesis cost— without compromise.
